Stanley-Laman Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Stanley-Laman Group’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,625	Closed	-$519K	–	348
2016 Q1	$519K	Sell	3,625 -17,822	-83%	-$2.53M	0.1%	170
2015 Q4	$3.31M	Buy	21,447 +367	+2%	+$53.6K	0.57%	54
2015 Q3	$3.01M	Sell	21,080 -2,100	-9%	-$294K	0.61%	48
2015 Q2	$3.33M	Buy	+23,180	New	+$3.31M	0.61%	54

Other funds holding TARO

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Stanley-Laman Group's TARO Position: Q2 2016 in Review

Stanley-Laman Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2016, closing a stake of 3,625 shares — an estimated $519K sold.

Stanley-Laman Group first reported a position in TARO in Q2 2015 and held it in 4 quarters. The position peaked at $3.33M in Q2 2015. 159 funds tracked by Wall St. Rank hold TARO as of Q2 2016.

Stanley-Laman Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2016 after selling out during the quarter.
Stanley-Laman Group sold 3,625 Taro Pharmaceutical Industries Ltd. shares in Q2 2016, an estimated $519K.
Stanley-Laman Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2015 and held it in 4 quarters.
Stanley-Laman Group's Taro Pharmaceutical Industries Ltd. position peaked at $3.33M in Q2 2015.
159 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.